Are results from immunotherapy in lung cancer durable?

Keytruda plus chemo still shows clear benefit 18 months on:

Keytruda in combination with chemotherapy for previously untreated advanced lung cancer appears to provide durable benefits, according to an update of a closely watched clinical trial.

The overall survival rate was 70 percent for the combination compared with 56 percent for chemo on its own.

Roche, Bristol, AstraZeneca are also chasing drug cocktails.

Giving Merck & Co’s immunotherapy drug Keytruda in combination with chemotherapy for previously untreated advanced lung cancer appears to provide durable benefits, according to an update of a closely watched clinical trial.

Learn More